Dissecting platelet proteomics to understand the pathophysiology of immune thrombocytopenia : studies in mouse models
(2022) In Blood Advances 6(11). p.3529-3534- Abstract
Immune thrombocytopenia (ITP) is an autoimmune disease characterized by enhanced platelet clearance and defective platelet production. Diagnosis by exclusion and trial-and-error treatment strategies is common practice, and despite the advancement in treatment options, many patients remain refractory. Although the existence of different pathophysiological entities is acknowledged, we are still far from stratifying and understanding ITP. To investigate, we sought to dissect the platelet proteome dynamics in so-called passive and active preclinical ITP mouse models, with which we propose to phenocopy respectively acute/newly diagnosed and persistent/chronic stages of ITP in humans. We obtained the platelet proteome at the thrombocytopenic... (More)
Immune thrombocytopenia (ITP) is an autoimmune disease characterized by enhanced platelet clearance and defective platelet production. Diagnosis by exclusion and trial-and-error treatment strategies is common practice, and despite the advancement in treatment options, many patients remain refractory. Although the existence of different pathophysiological entities is acknowledged, we are still far from stratifying and understanding ITP. To investigate, we sought to dissect the platelet proteome dynamics in so-called passive and active preclinical ITP mouse models, with which we propose to phenocopy respectively acute/newly diagnosed and persistent/chronic stages of ITP in humans. We obtained the platelet proteome at the thrombocytopenic stage and after platelet count recovery (reached naturally or by IVIg-treatment, depending on the model). Although most of the proteomic alterations were common to both ITP models, there were model-specific protein dynamics that accompanied and explained alterations in platelet aggregation responses, as measured in the passive ITP model. The expression dynamics observed in Syk may explain, extrapolated to humans and pending validation, the increased bleeding tendency of patients with ITP when treated with fostamatinib as third or later- as opposed to second line of treatment. We propose that the platelet proteome may give diagnostic and prognostic insights into ITP and that such studies should be pursued in humans.
(Less)
- author
- Martínez-Botía, Patricia ; Meinders, Marjolein ; De Cuyper, Iris M ; Eble, Johannes A ; Semple, John W LU and Gutiérrez, Laura
- organization
- publishing date
- 2022-06-14
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Animals, Blood Platelets, Disease Models, Animal, Humans, Mice, Proteome, Proteomics, Purpura, Thrombocytopenic, Idiopathic/drug therapy, Thrombocytopenia
- in
- Blood Advances
- volume
- 6
- issue
- 11
- pages
- 6 pages
- publisher
- American Society of Hematology
- external identifiers
-
- scopus:85132838848
- pmid:35298626
- ISSN
- 2473-9529
- DOI
- 10.1182/bloodadvances.2021006438
- language
- English
- LU publication?
- yes
- additional info
- © 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
- id
- d60dbbc4-c827-49ce-a603-818b92d4750d
- date added to LUP
- 2022-11-09 15:19:44
- date last changed
- 2025-01-27 02:02:51
@article{d60dbbc4-c827-49ce-a603-818b92d4750d,
abstract = {{<p>Immune thrombocytopenia (ITP) is an autoimmune disease characterized by enhanced platelet clearance and defective platelet production. Diagnosis by exclusion and trial-and-error treatment strategies is common practice, and despite the advancement in treatment options, many patients remain refractory. Although the existence of different pathophysiological entities is acknowledged, we are still far from stratifying and understanding ITP. To investigate, we sought to dissect the platelet proteome dynamics in so-called passive and active preclinical ITP mouse models, with which we propose to phenocopy respectively acute/newly diagnosed and persistent/chronic stages of ITP in humans. We obtained the platelet proteome at the thrombocytopenic stage and after platelet count recovery (reached naturally or by IVIg-treatment, depending on the model). Although most of the proteomic alterations were common to both ITP models, there were model-specific protein dynamics that accompanied and explained alterations in platelet aggregation responses, as measured in the passive ITP model. The expression dynamics observed in Syk may explain, extrapolated to humans and pending validation, the increased bleeding tendency of patients with ITP when treated with fostamatinib as third or later- as opposed to second line of treatment. We propose that the platelet proteome may give diagnostic and prognostic insights into ITP and that such studies should be pursued in humans.</p>}},
author = {{Martínez-Botía, Patricia and Meinders, Marjolein and De Cuyper, Iris M and Eble, Johannes A and Semple, John W and Gutiérrez, Laura}},
issn = {{2473-9529}},
keywords = {{Animals; Blood Platelets; Disease Models, Animal; Humans; Mice; Proteome; Proteomics; Purpura, Thrombocytopenic, Idiopathic/drug therapy; Thrombocytopenia}},
language = {{eng}},
month = {{06}},
number = {{11}},
pages = {{3529--3534}},
publisher = {{American Society of Hematology}},
series = {{Blood Advances}},
title = {{Dissecting platelet proteomics to understand the pathophysiology of immune thrombocytopenia : studies in mouse models}},
url = {{http://dx.doi.org/10.1182/bloodadvances.2021006438}},
doi = {{10.1182/bloodadvances.2021006438}},
volume = {{6}},
year = {{2022}},
}